JP2020537654A5 - - Google Patents

Download PDF

Info

Publication number
JP2020537654A5
JP2020537654A5 JP2020521453A JP2020521453A JP2020537654A5 JP 2020537654 A5 JP2020537654 A5 JP 2020537654A5 JP 2020521453 A JP2020521453 A JP 2020521453A JP 2020521453 A JP2020521453 A JP 2020521453A JP 2020537654 A5 JP2020537654 A5 JP 2020537654A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
peptide
acceptable salt
oligonucleotide conjugate
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020521453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537654A (ja
JP7320500B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/056205 external-priority patent/WO2019079386A1/en
Publication of JP2020537654A publication Critical patent/JP2020537654A/ja
Publication of JP2020537654A5 publication Critical patent/JP2020537654A5/ja
Priority to JP2023071470A priority Critical patent/JP7702444B2/ja
Application granted granted Critical
Publication of JP7320500B2 publication Critical patent/JP7320500B2/ja
Priority to JP2025032837A priority patent/JP2025087783A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020521453A 2017-10-17 2018-10-17 アンチセンス送達のための細胞透過性ペプチド Active JP7320500B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023071470A JP7702444B2 (ja) 2017-10-17 2023-04-25 アンチセンス送達のための細胞透過性ペプチド
JP2025032837A JP2025087783A (ja) 2017-10-17 2025-03-03 アンチセンス送達のための細胞透過性ペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573379P 2017-10-17 2017-10-17
US62/573,379 2017-10-17
PCT/US2018/056205 WO2019079386A1 (en) 2017-10-17 2018-10-17 CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023071470A Division JP7702444B2 (ja) 2017-10-17 2023-04-25 アンチセンス送達のための細胞透過性ペプチド

Publications (3)

Publication Number Publication Date
JP2020537654A JP2020537654A (ja) 2020-12-24
JP2020537654A5 true JP2020537654A5 (https=) 2021-11-11
JP7320500B2 JP7320500B2 (ja) 2023-08-03

Family

ID=66174189

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020521453A Active JP7320500B2 (ja) 2017-10-17 2018-10-17 アンチセンス送達のための細胞透過性ペプチド
JP2023071470A Active JP7702444B2 (ja) 2017-10-17 2023-04-25 アンチセンス送達のための細胞透過性ペプチド
JP2025032837A Pending JP2025087783A (ja) 2017-10-17 2025-03-03 アンチセンス送達のための細胞透過性ペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023071470A Active JP7702444B2 (ja) 2017-10-17 2023-04-25 アンチセンス送達のための細胞透過性ペプチド
JP2025032837A Pending JP2025087783A (ja) 2017-10-17 2025-03-03 アンチセンス送達のための細胞透過性ペプチド

Country Status (6)

Country Link
US (2) US12138312B2 (https=)
EP (1) EP3697422A4 (https=)
JP (3) JP7320500B2 (https=)
MA (1) MA50834A (https=)
TW (2) TW202423453A (https=)
WO (1) WO2019079386A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52148A (fr) * 2018-03-16 2021-01-20 Sarepta Therapeutics Inc Peptides chimères pour administration d'antisens
WO2021150867A1 (en) * 2020-01-24 2021-07-29 Sarepta Therapeutics, Inc. Designing antisense oligonucleotide delivery peptides by interpretable machine learning
US20240041050A1 (en) * 2020-12-16 2024-02-08 Pioneer Hi-Bred International, Inc. Cell penetrating peptide mediated rna transduction within insect cells
WO2023034515A2 (en) * 2021-09-03 2023-03-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
CN114380886B (zh) * 2022-01-26 2022-10-21 深圳深创生物药业有限公司 一种肿瘤靶向多肽、多肽偶联药物及其应用
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
EP4612292A1 (en) * 2022-11-02 2025-09-10 Sarepta Therapeutics, Inc. Formulation of an antisense oligomer conjugate
TW202519660A (zh) * 2023-08-02 2025-05-16 美商薩羅塔治療公司 針對反義寡聚物遞送之非標準細胞穿透肽
WO2026080471A2 (en) 2024-10-07 2026-04-16 Flagship Pioneering Innovations Vi, Llc Compositions of trem conjugates and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2735568T3 (da) * 2006-05-10 2017-11-13 Sarepta Therapeutics Inc Oligonukleotidanaloger med kationiske bindinger mellem underenheder
EP3443976A1 (en) * 2007-06-29 2019-02-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2012150960A1 (en) * 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
KR102451116B1 (ko) * 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, n-말단 상에 관능화된 아미노산 유도체
KR102240217B1 (ko) * 2012-09-25 2021-04-14 젠자임 코포레이션 근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드
WO2014124952A1 (en) 2013-02-12 2014-08-21 Syddansk Universitet "clickable" alkyne-lna oligonucleotides
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
MA52148A (fr) * 2018-03-16 2021-01-20 Sarepta Therapeutics Inc Peptides chimères pour administration d'antisens

Similar Documents

Publication Publication Date Title
JP2020537654A5 (https=)
JP5271913B2 (ja) 化合物
JP2020503009A5 (https=)
JP2019514426A5 (https=)
JP2021532784A5 (https=)
JP2020022483A5 (https=)
RU2005118421A (ru) 2'-разветвленные нуклеозиды и мутация flaviviridae
CN1414854A (zh) 膦酸酯化合物
US20110245458A1 (en) Peptide nucleic acid monomers and oligomers
CA3007065C (en) Salts of conjugates for cancer therapy
CN101415719A (zh) 生产2’-脱氧-β-L-核苷的方法
JP2021182946A5 (https=)
CN107074911B (zh) 肽核酸单体和低聚体
JP2020525502A5 (https=)
SA98190103B1 (ar) مركبات 5‘-ديوكسي-سيتيدين 5 deoxy cytidine -وإستخدامها كعوامل مضادة لورم anti tumor
JP2018525015A5 (https=)
US10239910B2 (en) Process for the preparation of sofosbuvir
JP2020537652A5 (https=)
JPWO2023127752A5 (https=)
JPWO2020028254A5 (https=)
JP2018518167A5 (https=)
JPWO2023178230A5 (https=)
JPWO2019178479A5 (https=)
AU2012216500B2 (en) Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
JPWO2022140535A5 (https=)